United States:
Routine Trial-And-Error Approach To Protein Formulation Is Not Sufficient To Establish Obviousness Absent A Reasonable Expectation Of Success In Achieving The Claimed Formulation, PTAB Litigation Blog
11 January 2017
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
On December 22, 2016, in a final written decision in
IPR2015-01537, the PTAB rejected an obviousness challenge brought
by Momenta Pharmaceuticals, Inc. against a patent owned by
Bristol-Myers Squibb directed to certain stable liquid formulations
of the therapeutic molecule CTLA4Ig (a fusion protein commercially
available as Orencia) for subcutaneous delivery.
Read the full article at
ptablitigationblog.com.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
